Skip to content
Screener

Regenxbio RGNX Total Liabilities & Equity

Total Liabilities & Equity at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$41.73B+9.2%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$3.19B-13.4%
Biogen logo
BiogenBIIB
$32.09B+13.3%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$11.72B+57.2%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$228.19M-24.2%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.26B-3.2%

Other financials

Income statement

See full
Revenue$108.0M+406%
Gross profit$14.9M+35.7%
Operating income$29.3M+146%
Net income$22.7M+132%
EPS (diluted)$0.43+131%

Balance sheet

See full
Cash & equivalents$36.5M-54.1%
Total debt$69.0M-11.3%
Total equity$71.8M-66.4%
Total assets$386.6M-33.5%

Cash flow

See full
Operating cash flow-$62.2M-26.1%
CapEx$760.0K+94.4%
Free cash flow-$63.0M-26.7%

Valuation

See full
Market cap$707.66M+87.8%
Enterprise value$740.13M+97.4%
P/S4.1×+1.6×

Profitability

See full
Gross margin59.7%+1.0pp
Operating margin-94.1%-9.3pp
Net margin-112.6%-0.1pp
FCF margin-143.1%-456pp

Returns & leverage

See full
Return on equity-137.6%-817pp
Debt / equity+0.6×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Regenxbio’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:15 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336725
Line itemJune 30, 2026December 31, 2025
Stockholders’ equity
Preferred stock; $0.0001 par value; 10,000 shares authorized, no shares issued and outstanding at June 30, 2026 and December 31, 2025
Common stock; $0.0001 par value; 100,000 shares authorized at June 30, 2026 and December 31, 2025; 54,164 and 50,892 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively55
Additional paid-in capital1,266,0041,229,442
Accumulated other comprehensive loss(875)(687)
Accumulated deficit(1,193,369)(1,126,027)
Total stockholders’ equity71,765102,733
Total liabilities and stockholders’ equity$386,618$453,032

Item 1. Financial Statements.

FAQ

What is Regenxbio's total liabilities & equity?
Regenxbio (RGNX) reported total liabilities & equity of $386.62M in Q2 2026.
How has Regenxbio's total liabilities & equity changed year-over-year?
Regenxbio's total liabilities & equity decreased by 33.5% year-over-year, from $581.03M to $386.62M.
What is the long-term trend for Regenxbio's total liabilities & equity?
Over 5 years (2020 to 2025), Regenxbio's total liabilities & equity has grown at a -8.5% compound annual growth rate (CAGR), from $708.16M to $453.03M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Regenxbio's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude